Meeting
2013 ASCO Annual Meeting
ROCHOP study: A phase III randomized study of CHOP compared to romidepsin-CHOP in untreated peripheral T-cell lymphoma.
Authors
Richard Delarue
Hopital Necker, Paris, France
Richard Delarue , Pier Luigi Zinzani , Mark S. Hertzberg , Won Seog Kim , Dolores Caballero , Antonio Pezzutto , Marc Andre , Maria Gomes Da Silva , Philippe Gaulard , Bertrand Coiffier
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
2012-001580-68
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS8616)
DOI
10.1200/jco.2013.31.15_suppl.tps8616
Abstract #
TPS8616
Poster Bd #
57E
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Development of novel backbones for the treatment of peripheral T-cell lymphoma (PTCL): The pralatrexate/ romidepsin doublet.
First Author: Jennifer Effie Amengual
Poster
2015 ASCO Annual Meeting
Phase II study of Hyper-CVAD with pegylated liposomal doxorubicin alternating with methotrexate and cytarabine (HCVIDD/MA) in patients with newly diagnosed T- and NK-cell lymphoma (T/NKCL).
First Author: Dai Chihara
Poster
2022 ASCO Annual Meeting
frontMIND: A phase III, randomized, double-blind study of tafasitamab + lenalidomide + R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma.
First Author: Umberto Vitolo
Poster
2021 ASCO Annual Meeting
Multicenter phase II study of romidepsin plus lenalidomide for patients with previously untreated peripheral T-cell lymphoma (PTCL).
First Author: Jia Ruan